Genk

• A 24-Week Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF) ( … Ended recruitment
  2024-514283-40-00 4 2024-12-19 Pulmonary Hypertension
• Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph … Ended recruitment
  2023-505989-29-00 5 2024-11-21 Extensive stage small cell lung cancer (ES-SCLC)
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu … Ended recruitment
  2023-509762-38-00 5 2024-08-01 Respiratory Syncytial Virus Infections
• A study concerning the influence of tubal flushing with oil on pregnancy and live birth in women with fertility problems Ended recruitment
  2023-508896-35-00 6 2024-07-12 Infertile women with at least one patent tube at Hysterosalpingo-foam
• A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) w … Ended recruitment
  2024-512023-37-00 4 2024-06-27 Prostate cancer
• Treat-CMV Ended recruitment
  2022-500714-25-01 5 2024-06-19 congenital CMV infection
• The effect of nocturnal dexmedetomidine on postoperative sleep quality and fatigue after major surgery in elderly patients: DEXSLEEP study Ended recruitment
  2023-510403-22-00 6 2024-06-03 Patients aged 60 years or older undergoing major surgery (thoracoscopi
• A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intraves … Ended recruitment
  2023-507685-10-00 5 2024-05-30 High-Risk Non-muscle-invasive Bladder Cancer
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended recruitment
  2023-506669-70-00 5 2024-04-30 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
• Subcutaneous infliximab after a previous intravenous dose optimization (AMARETTO trial) Ended recruitment
  2023-508166-15-00 6 2024-04-29 Ulcerative colitis (UC), Inflammatory bowel disease type unclassified
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal- … Ended recruitment
  2022-502446-27-00 5 2024-02-26 Relapsed or Refractory Myeloma
• A Phase 3b/4 Randomized, Double-Blind, Double-Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib V … Ended recruitment
  2022-502578-18-00 11 2023-11-07 Rheumatoid Arthritis
• Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma Ended recruitment
  2023-503652-27-00 5 2023-10-06 Melanoma
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A study to test trimodulin in adult hospitalized patients with severe pneumonia Ended recruitment
  2022-501352-28-00 5 2023-06-07 Severe community-acquired pneumonia (sCAP)
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenanc … Ended recruitment
  2023-509320-17-00 6 2023-03-28 non-radiographic axial spondyloarthritis
• Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn's Disease Ended recruitment
  2023-504740-33-00 5 2022-11-22 Fistulizing perianal Crohn's Disease
• A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i … Ended recruitment
  2023-509859-13-00 5 2022-11-09 Relapsed or Refractory Multiple Myeloma (RRMM)
• A study to learn more about how well elinzanetant works and how safe it is compared to placebo for the treatment of hot flashes caused by an … Ended recruitment
  2023-508265-33-00 5 2022-10-13 Vasomotor symptoms caused by adjuvant endocrine therapy in women with,
• Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic P … Ended recruitment
  2024-511126-31-00 5 2022-08-16 Non-obstructive Coronary Artery Disease

Showing 73–96 of 135 trials